A Phase 3 interventional study of Adalimumab and Baricitinib in Rheumatoid Arthritis, sponsored by Eli Lilly and Company. Completed at 213 sites in 28 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-18.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing baricitinib in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, 1 of them phase 3. baricitinib · Arthritis, Rheumatoid.
Among the 23 studies testing baricitinib in Arthritis, Rheumatoid, this one is the 3rd largest by enrollment, is one of 3 that started in 2012, is one of 8 in phase 3, and was the 5th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →5 of the 23 studies testing baricitinib in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:
University Hospital, Toulouse · Sites in France
Ages 18–65
Chinese University of Hong Kong · Sites in Hong Kong
Ages 18–65
Galvani Bioelectronics · Sites in United States, Netherlands
Ages 22–75
University of Nebraska · Sites in United States
Ages 19+
Tanta University · Sites in Egypt
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
baricitinib: first FDA approval 2018 (OLUMIANT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 8 · Phase 4 9
First in 2007; this study’s year is marked. 3 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,307 is above the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 290 across the 23 interventional studies. Of the 16 that completed or were terminated, 13 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 23 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
35 studies in Arthritis, Rheumatoid by Eli Lilly and Company: 2 open now, 2 under way, none of them phase 3. Of 33 finished, 30 (91%) have results posted.
Among the 35 studies in Arthritis, Rheumatoid by Eli Lilly and Company, this one is the 3rd largest by enrollment, is one of 5 that started in 2012, is one of 11 in phase 3, and was the 20th registered.
Eli Lilly and Company’s Arthritis, Rheumatoid studies by the year they started, since 2005.
1 of the studies testing baricitinib in Arthritis, Rheumatoid that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05003310Galvani BioelectronicsConsideRAte Study - Splenic Stimulation for RA | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies testing baricitinib in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 35 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether baricitinib is superior to placebo in the treatment of participants with moderately to severely active Rheumatoid Arthritis (RA) who have had an inadequate response to methotrexate (MTX) treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo administered orally once daily through Week 24 and placebo administered by subcutaneous (SC) injection every 2 weeks through Week 50. At Week 24, participants were given baricitinib 4 milligram (mg) orally once daily through Week 52. Starting at Week 16, participants who were nonresponders were rescued with baricitinib 4 mg orally daily through Week 52. Participants continued to take background methotrexate (MTX) therapy throughout study.
Drug: Methotrexate · Drug: Adalimumab Placebo · Drug: Baricitinib Placebo
Baricitinib 4 mg administered orally once daily through Week 52 and an adalimumab placebo SC injection every 2 weeks through Week 50. Starting at Week 16, nonresponder participants originally randomized to baricitinib continued to receive baricitinib 4 mg administered orally once daily through Week 52. Participants continued to take background methotrexate (MTX) therapy throughout study.
Drug: Baricitinib · Drug: Methotrexate · Drug: Adalimumab Placebo
Adalimumab 40 mg administered by SC injection every 2 weeks through Week 50 and baricitinib placebo orally once daily through Week 52. Starting at Week 16, participants who were nonresponders were rescued with baricitinib 4 mg orally once daily through Week 52. Participants continued to take background methotrexate (MTX) therapy throughout study.
Drug: Adalimumab · Drug: Methotrexate · Drug: Baricitinib Placebo
Administered SC
Administered orally
Also known as: LY 3009104
Administered orally
Adalimumab placebo administered SC.
Baricitinib placebo administered orally.
Percentage of Participants Achieving American College of Rheumatology 20% Improvement (ACR20)
ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). "ACR20 Responder" is a participant who has at least 20% improvement in both tender and swollen joint counts and in at least 3 of the following 5 criteria: Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity using visual analog scale (VAS), Health Assessment Questionnaire-Disability Index (HAQ-DI), pain due to arthritis, and high-sensitivity C-reactive protein (hsCRP). Participants with missing responses and participants who discontinued study or drug or were rescued before analysis timepoint were deemed non-responders.
Time frame: Week 12
Change From Baseline in the Modified Total Sharp Score (mTSS)
X-rays of the hands/wrists and feet were scored for structural progression as measured using the mTSS. This methodology quantified the extent of bone erosions and joint space narrowing for 44 and 42 joints, with higher scores representing greater damage. The mTSS at a time point is the sum of the erosion (range from 0 to 280) and JSN (range from 0 to 168) scores, for a maximum score of 448.
Time frame: Baseline, Week 24
Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score
The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty (0 \[without any difficulty\], 1 \[with some difficulty\], 2 \[with much difficulty\], and 3 \[unable to do\]) when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate the HAQ-DI score, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition.
Time frame: Baseline, Week 12
Change From Baseline in the Disease Activity Score Based on a 28-Joint Count and High-sensitivity C-reactive Protein (DAS28-hsCRP)
Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), C-reactive protein (CRP) (milligrams per liter), and Patient's Global Assessment of Disease Activity using visual analog scale (VAS) (participant global VAS). DAS28 was calculated using following formula: DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*Patient's Global VAS+0.96. Scores ranged 1.0-9.4, where lower scores indicated less disease activity.
Time frame: Baseline, Week 12
Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) and 70% (ACR70) Response
ACR50 and ACR70 Responder Index is a composite of clinical, laboratory, and functional measures in RA. ACR50 and ACR70 Responder is a participant who has at least 50% or 70% improvement, respectively, in both tender and swollen joint counts and in at least 3 of the following 5 criteria: Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity, HAQ-DI, pain due to arthritis, and hsCRP. Participants with missing responses and participants who discontinued study or drug or were rescued before analysis time point were deemed non-responders.
Time frame: Week 12, Week 24, Week 52
Change From Baseline in Clinical Disease Activity Index (CDAI) Score
The CDAI is a tool for measurement of disease activity in RA that does not require a laboratory component and was scored by the investigative site. It integrates TJC28 (scored 0-28 with higher scores indicating higher disease activity), SJC28 (scored 0-28 with higher scores indicating higher disease activity), Patient's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity), and Physician's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity). The CDAI is calculated by summing the values of the 4 components. CDAI scores range from 0 to 76; lower scores indicated lower disease activity. A negative change from baseline indicates improvement in condition.
Time frame: Baseline, Week 12, Week 24, Week 52
Percentage of Participants Achieving Simplified Disease Activity Index (SDAI) Score ≤3.3
SDAI is a tool for measurement of disease activity in RA that integrates TJC28, SJC28, acute phase response using C-reactive protein (milligrams per liter), Patient's Global Assessment of Disease Activity using VAS centimeters (cm), and Physician's Global Assessment of Disease Activity using VAS (cm). The SDAI is calculated by summing the values of the 5 components. Lower scores indicated less disease activity. An index-based definition of remission occurs with an SDAI score ≤3.3.
Time frame: Week 12, Week 24, Week 52
Percentage of Participants Achieving American College of Rheumatology European League Against Rheumatism (ACR/EULAR) Remission - Boolean Remission
The ACR/EULAR definitions of RA remission includes a Boolean-based definition. The Boolean-based definition of remission occurs when all 4 of the following criteria are met at the same visit: TJC28 ≤1, SJC28 ≤1, acute phase response using C-reactive protein (milligrams per deciliter) ≤1, Patient's Global Assessment of Disease Activity using VAS (cm) ≤1.
Time frame: Week 12, Week 24, Week 52
Median of Individual Participant Mean Duration of Morning Joint Stiffness in the Prior 7 Days as Collected in Electronic Diaries
Participants recorded the duration of their morning joint stiffness (MJS) in hours and minutes into electronic diaries daily. If morning joint stiffness duration was longer than 12 hours (720 minutes), it was truncated to 720 minutes for statistical presentations and analyses. The average value across the 7 days preceding each visit was calculated. A decrease in duration of morning joint stiffness indicated an improvement in the participant's condition.
Time frame: Week 12
Mean Severity of Morning Joint Stiffness Numeric Rating Scale (NRS) in the Prior 7 Days as Collected in Electronic Diaries
Participants rated the severity of their morning joint stiffness by selecting a number from 0 to 10 that best described their overall level of morning joint stiffness from the time they woke up, where 0 represents "no joint stiffness" and 10 represents "joint stiffness as bad as you can imagine". Participants reported their severity daily in electronic diaries. The average value across the 7 days preceding each visit was calculated.
Time frame: Week 12
Mean Worst Tiredness Numeric Rating Scale (NRS) in the Prior 7 Days as Collected in Electronic Diaries
Participants rated their tiredness by selecting a number from 0 to 10 that best described their worst tiredness during the last 24 hours, where 0 represents "no tiredness" and 10 represents "as bad as you can imagine". Participants reported their worst tiredness in electronic diaries. The average value across the 7 days preceding each visit is calculated.
Time frame: Week 12
Mean Worst Joint Pain NRS in the Prior 7 Days as Collected in Electronic Diaries
Participants rated their joint pain by selecting a number from 0 to 10 that best described their worst joint pain during the last 24 hours, where 0 represents "no pain" and 10 represents "pain as bad as you can imagine". Participants reported their worst joint pain in daily electronic diaries. The average value across the 7 days preceding each visit was calculated.
Time frame: Week 12
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale Scores
The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale is a brief 13-item, symptom-specific questionnaire that specifically assesses the participant's self-reported severity of fatigue and its impact upon daily activities and functioning. The FACIT-F uses a numeric rating scale of 0 ("Not at all") to 4 ("Very much") for each item to assess fatigue and its impact in the past 7 days. Total scores range from 0 to 52, with higher scores indicating less fatigue.
Time frame: Baseline, Week 12, Week 24, Week 52
Change From Baseline in Mental Component Score (MCS), Physical Component Score (PCS) of the Medical Outcomes Study 36-Item Short Form Health Survey Version 2 Acute (SF-36v2 Acute)
The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (mental \[MCS\] and physical \[PCS\]). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with higher scores indicating better health status or functioning.
Time frame: Baseline, Week 12, Week 24, Week 52
Change From Baseline in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Scores
European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. One component consists of a descriptive system of the respondent's health comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1, and the United States (US) algorithm, with scores ranging from -0.109 to 1. A higher score indicates better health state.
Time frame: Baseline, Week 12, Week 24, Week 52
Change From Baseline in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Scores (Self-Perceived Health)
A second component of the EQ-5D-5L is a self-perceived health score which is assessed using a VAS that ranges from 0 to 100 millimeter (mm), where 0 indicates the worst health you can imagine and 100 indicates the best health you can imagine.
Time frame: Baseline, Week 12, Week 24, Week 52
Change From Baseline in Work Productivity and Activity Impairment-Rheumatoid Arthritis (WPAI-RA) Scores
The Work Productivity and Activity Impairment-Rheumatoid Arthritis (WPAI-RA) questionnaire was developed to measure the effect of general health and symptom severity on work productivity and regular activities in the 7 days prior to the visit. It contains 6 items covering overall work productivity (health), overall work productivity (symptom), impairment of regular activities (health), and impairment of regular activities (symptom). Scores are calculated as impairment percentages. The WPAI-RA yields four types of scores: Absenteeism (work time missed), Presenteeism (impairment at work), Work productivity loss (overall work impairment), and Activity impairment.
Time frame: Baseline, Week 12, Week 24, Week 52
Change From Baseline in Joint Space Narrowing (JSN) and Bone Erosion Scores
X-rays of the hands/wrists and feet were assessed for joint space narrowing (JSN) and bone erosions. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, is scored from 0 to 4, with 0 indicating no (normal) JSN and 4 indicating complete loss of joint space, bony ankylosis or luxation. JSN scores ranged from 0-168. A score of 0 would indicate no change and higher scores represent a worsening of joint space narrowing. The bone erosion score is a summary of erosion severity in 32 joints of the hands and 12 joints of the feet. Each joint is scored according to the surface area involved from 0 to 5 for hand joints and 0 to 10 for the foot joints, with 0 indicating no erosion and the highest score (5 for the hand and 10 for the foot) indicating extensive loss of bone from more than one half of the articulating bone. Erosion scores ranged from 0 (no erosion) to 280 (high erosion).
Time frame: Baseline, Week 24, Week 52
Population Pharmacokinetics (PK): Peak Concentration at Steady State (Cmax,ss) of Baricitinib
Time frame: Week 0: 15 and 60 minutes postdose; Week 4: 2 to 4 hours post-dose; Week 8: 4 to 6 hours post-dose; Week 12; Week 12; Week 24; Week 32: Pre-dose
Population PK: Area Under the Concentration Versus Time Curve at a Dosing Interval at Steady State (AUCtau,ss) of Baricitinib
Time frame: Week 0: 15 and 60 minutes postdose; Week 4: 2 to 4 hours post-dose; Week 8: 4 to 6 hours post-dose; Week 12; Week 12; Week 24; Week 32: Pre-dose
| Milestone | Placebo | Baricitinib | Adalimumab |
|---|---|---|---|
| Started | 489 | 488 | 330 |
| Received at least 1 dose of study drug | 488 | 487 | 330 |
| Rescued | 128 | 35 | 40 |
| Completed | 438 | 459 | 307 |
| Not completed | 51 | 29 | 23 |
| Withdrew: Adverse event | 15 | 18 | 7 |
| Withdrew: Death | 0 | 2 | 0 |
| Withdrew: Entry criteria not met | 0 | 1 | 1 |
| Withdrew: Lack of efficacy | 15 | 1 | 3 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 |
| Withdrew: Sponsor decision | 4 | 0 | 0 |
| Withdrew: Withdrawal by subject | 15 | 5 | 12 |
| Withdrew: Randomized but not treated | 1 | 1 | 0 |
| Milestone | Placebo | Baricitinib | Adalimumab |
|---|---|---|---|
| Started | 310 | 424 | 267 |
| Received at least 1 dose of study drug | 306 | 424 | 267 |
| Rescued | 5 | 8 | 11 |
| Completed | 294 | 402 | 252 |
| Not completed | 16 | 22 | 15 |
| Withdrew: Adverse event | 10 | 16 | 5 |
| Withdrew: Death | 1 | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
| Withdrew: Physician decision | 0 | 1 | 0 |
| Withdrew: Sponsor decision | 1 | 2 | 0 |
| Withdrew: Withdrawal by subject | 4 | 3 | 7 |
| Milestone | Placebo | Baricitinib | Adalimumab |
|---|---|---|---|
| Started | 0 | 227 | 0 |
| Completed | 0 | 196 | 0 |
| Not completed | 0 | 31 | 0 |
| Withdrew: Adverse event | 0 | 15 | 0 |
| Withdrew: Death | 0 | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 7 | 0 |
| Withdrew: Withdrawal by subject | 0 | 8 | 0 |
| Milestone | Placebo | Baricitinib | Adalimumab |
|---|---|---|---|
| Started | 33 | 76 | 20 |
| Completed | 33 | 76 | 20 |
| Not completed | 0 | 0 | 0 |
ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). "ACR20 Responder" is a participant who has at least 20% improvement in both tender and swollen joint counts and in at least 3 of the following 5 criteria: Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity using visual analog scale (VAS), Health Assessment Questionnaire-Disability Index (HAQ-DI), pain due to arthritis, and high-sensitivity C-reactive protein (hsCRP). Participants with missing responses and participants who discontinued study or drug or were rescued before analysis timepoint were deemed non-responders.
| percentage of participants | Placebo | Baricitinib | Adalimumab |
|---|---|---|---|
| Percentage of Participants Achieving American College of Rheumatology 20% Improvement (ACR20) | 40.2 | 69.6 | 61.2 |
X-rays of the hands/wrists and feet were scored for structural progression as measured using the mTSS. This methodology quantified the extent of bone erosions and joint space narrowing for 44 and 42 joints, with higher scores representing greater damage. The mTSS at a time point is the sum of the erosion (range from 0 to 280) and JSN (range from 0 to 168) scores, for a maximum score of 448.
| units on a scale | Placebo | Baricitinib | Adalimumab |
|---|---|---|---|
| Change From Baseline in the Modified Total Sharp Score (mTSS) | 0.84 ± 2.32 | 0.35 ± 1.59 | 0.29 ± 1.47 |
The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty (0 \[without any difficulty\], 1 \[with some difficulty\], 2 \[with much difficulty\], and 3 \[unable to do\]) when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate the HAQ-DI score, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition.
| units on a scale | Placebo | Baricitinib | Adalimumab |
|---|---|---|---|
| Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score | -0.33 ± 0.51 | -0.65 ± 0.59 | -0.56 ± 0.54 |
Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), C-reactive protein (CRP) (milligrams per liter), and Patient's Global Assessment of Disease Activity using visual analog scale (VAS) (participant global VAS). DAS28 was calculated using following formula: DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*Patient's Global VAS+0.96. Scores ranged 1.0-9.4, where lower scores indicated less disease activity.
| units on a scale | Placebo | Baricitinib | Adalimumab |
|---|---|---|---|
| Change From Baseline in the Disease Activity Score Based on a 28-Joint Count and High-sensitivity C-reactive Protein (DAS28-hsCRP) | -1.01 ± 1.12 | -2.27 ± 1.22 | -1.98 ± 1.28 |
ACR50 and ACR70 Responder Index is a composite of clinical, laboratory, and functional measures in RA. ACR50 and ACR70 Responder is a participant who has at least 50% or 70% improvement, respectively, in both tender and swollen joint counts and in at least 3 of the following 5 criteria: Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity, HAQ-DI, pain due to arthritis, and hsCRP. Participants with missing responses and participants who discontinued study or drug or were rescued before analysis time point were deemed non-responders.
| percentage of participants | Placebo | Baricitinib | Adalimumab |
|---|---|---|---|
| ACR50 Week 12 | 16.8 | 45.0 | 34.8 |
| ACR50 Week 24 | 19.3 | 50.5 | 45.5 |
| ACR50 Week 52 | NA | 55.9 | 47.0 |
| ACR70 Week 12 | 4.7 | 18.9 | 12.7 |
| ACR70 Week 24 | 8.0 | 29.8 | 21.8 |
| ACR70 Week 52 | NA | 37.2 | 30.6 |
The CDAI is a tool for measurement of disease activity in RA that does not require a laboratory component and was scored by the investigative site. It integrates TJC28 (scored 0-28 with higher scores indicating higher disease activity), SJC28 (scored 0-28 with higher scores indicating higher disease activity), Patient's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity), and Physician's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity). The CDAI is calculated by summing the values of the 4 components. CDAI scores range from 0 to 76; lower scores indicated lower disease activity. A negative change from baseline indicates improvement in condition.
| units on a scale | Placebo | Baricitinib | Adalimumab |
|---|---|---|---|
| Week 12 | -13.53 ± 13.88 | -23.00 ± 12.66 | -20.42 ± 13.47 |
| Week 24 | -14.21 ± 15.13 | -25.04 ± 13.61 | -22.92 ± 14.63 |
| Week 52 | NA ± NA | -26.44 ± 14.42 | -23.48 ± 15.28 |
SDAI is a tool for measurement of disease activity in RA that integrates TJC28, SJC28, acute phase response using C-reactive protein (milligrams per liter), Patient's Global Assessment of Disease Activity using VAS centimeters (cm), and Physician's Global Assessment of Disease Activity using VAS (cm). The SDAI is calculated by summing the values of the 5 components. Lower scores indicated less disease activity. An index-based definition of remission occurs with an SDAI score ≤3.3.
| percentage of participants | Placebo | Baricitinib | Adalimumab |
|---|---|---|---|
| Week 12 | 1.8 | 8.4 | 7.3 |
| Week 24 | 3.1 | 16.0 | 13.6 |
| Week 52 | NA | 22.6 | 17.9 |
The ACR/EULAR definitions of RA remission includes a Boolean-based definition. The Boolean-based definition of remission occurs when all 4 of the following criteria are met at the same visit: TJC28 ≤1, SJC28 ≤1, acute phase response using C-reactive protein (milligrams per deciliter) ≤1, Patient's Global Assessment of Disease Activity using VAS (cm) ≤1.
| percentage of participants | Placebo | Baricitinib | Adalimumab |
|---|---|---|---|
| Week 12 | 1.0 | 7.2 | 5.2 |
| Week 24 | 2.7 | 12.1 | 10.0 |
| Week 52 | NA | 15.6 | 13.0 |
Participants recorded the duration of their morning joint stiffness (MJS) in hours and minutes into electronic diaries daily. If morning joint stiffness duration was longer than 12 hours (720 minutes), it was truncated to 720 minutes for statistical presentations and analyses. The average value across the 7 days preceding each visit was calculated. A decrease in duration of morning joint stiffness indicated an improvement in the participant's condition.
| Minutes | Placebo | Baricitinib | Adalimumab |
|---|---|---|---|
| Median of Individual Participant Mean Duration of Morning Joint Stiffness in the Prior 7 Days as Collected in Electronic Diaries | 60.0 (60.0 to 75.0) | 27.1 (20.0 to 30.0) | 36.6 (30.0 to 45.7) |
Participants rated the severity of their morning joint stiffness by selecting a number from 0 to 10 that best described their overall level of morning joint stiffness from the time they woke up, where 0 represents "no joint stiffness" and 10 represents "joint stiffness as bad as you can imagine". Participants reported their severity daily in electronic diaries. The average value across the 7 days preceding each visit was calculated.
| units on a scale | Placebo | Baricitinib | Adalimumab |
|---|---|---|---|
| Mean Severity of Morning Joint Stiffness Numeric Rating Scale (NRS) in the Prior 7 Days as Collected in Electronic Diaries | 4.1 ± 2.3 | 3.0 ± 2.2 | 3.4 ± 2.3 |
Participants rated their tiredness by selecting a number from 0 to 10 that best described their worst tiredness during the last 24 hours, where 0 represents "no tiredness" and 10 represents "as bad as you can imagine". Participants reported their worst tiredness in electronic diaries. The average value across the 7 days preceding each visit is calculated.
| units on a scale | Placebo | Baricitinib | Adalimumab |
|---|---|---|---|
| Mean Worst Tiredness Numeric Rating Scale (NRS) in the Prior 7 Days as Collected in Electronic Diaries | 4.4 ± 2.3 | 3.6 ± 2.2 | 3.9 ± 2.3 |
Participants rated their joint pain by selecting a number from 0 to 10 that best described their worst joint pain during the last 24 hours, where 0 represents "no pain" and 10 represents "pain as bad as you can imagine". Participants reported their worst joint pain in daily electronic diaries. The average value across the 7 days preceding each visit was calculated.
| units on a scale | Placebo | Baricitinib | Adalimumab |
|---|---|---|---|
| Mean Worst Joint Pain NRS in the Prior 7 Days as Collected in Electronic Diaries | 4.6 ± 2.2 | 3.4 ± 2.2 | 4.0 ± 2.3 |
The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale is a brief 13-item, symptom-specific questionnaire that specifically assesses the participant's self-reported severity of fatigue and its impact upon daily activities and functioning. The FACIT-F uses a numeric rating scale of 0 ("Not at all") to 4 ("Very much") for each item to assess fatigue and its impact in the past 7 days. Total scores range from 0 to 52, with higher scores indicating less fatigue.
| units on a scale | Placebo | Baricitinib | Adalimumab |
|---|---|---|---|
| Week 12 | 6.8 ± 9.9 | 9.6 ± 10.4 | 9.5 ± 10.1 |
| Week 24 | 6.6 ± 10.4 | 10.4 ± 10.8 | 9.9 ± 11.2 |
| Week 52 | NA ± NA | 10.8 ± 10.9 | 9.8 ± 10.8 |
The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (mental \[MCS\] and physical \[PCS\]). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with higher scores indicating better health status or functioning.
| units on a scale | Placebo | Baricitinib | Adalimumab |
|---|---|---|---|
| MCS Week 12 | 3.2 ± 10.3 | 3.3 ± 10.5 | 3.8 ± 10.8 |
| MCS Week 24 | 2.2 ± 11.4 | 3.8 ± 10.9 | 3.9 ± 11.6 |
| MCS Week 52 | NA ± NA | 4.0 ± 10.8 | 3.7 ± 11.2 |
| PCS Week 12 | 4.3 ± 7.1 | 8.9 ± 8.1 | 7.6 ± 8.2 |
| PCS Week 24 | 4.6 ± 7.8 | 9.9 ± 8.2 | 8.3 ± 9.1 |
| PCS Week 52 | NA ± NA | 10.4 ± 9.0 | 9.0 ± 9.2 |
European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. One component consists of a descriptive system of the respondent's health comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1, and the United States (US) algorithm, with scores ranging from -0.109 to 1. A higher score indicates better health state.
| units on a scale | Placebo | Baricitinib | Adalimumab |
|---|---|---|---|
| Index Score (US Algorithm) Week 12 | 0.073 ± 0.151 | 0.132 ± 0.156 | 0.130 ± 0.159 |
| Index Score (US Algorithm) Week 24 | 0.065 ± 0.168 | 0.143 ± 0.168 | 0.137 ± 0.167 |
| Index Score (US Algorithm) Week 52 | NA ± NA | 0.152 ± 0.163 | 0.141 ± 0.189 |
| Index Score (UK Algorithm) Week 12 | 0.107 ± 0.221 | 0.188 ± 0.228 | 0.186 ± 0.232 |
| Index Score (UK Algorithm) Week 24 | 0.094 ± 0.247 | 0.203 ± 0.244 | 0.195 ± 0.245 |
| Index Score (UK Algorithm) Week 52 | NA ± NA | 0.215 ± 0.235 | 0.198 ± 0.273 |
A second component of the EQ-5D-5L is a self-perceived health score which is assessed using a VAS that ranges from 0 to 100 millimeter (mm), where 0 indicates the worst health you can imagine and 100 indicates the best health you can imagine.
| millimeter | Placebo | Baricitinib | Adalimumab |
|---|---|---|---|
| Self-Perceived Health Week 12 | 7.9 ± 26.2 | 14.9 ± 25.8 | 10.7 ± 26.9 |
| Self-Perceived Health Week 24 | 5.6 ± 27.1 | 17.5 ± 28.3 | 12.6 ± 28.9 |
| Self-Perceived Health Week 52 | NA ± NA | 19.9 ± 28.0 | 13.3 ± 29.7 |
The Work Productivity and Activity Impairment-Rheumatoid Arthritis (WPAI-RA) questionnaire was developed to measure the effect of general health and symptom severity on work productivity and regular activities in the 7 days prior to the visit. It contains 6 items covering overall work productivity (health), overall work productivity (symptom), impairment of regular activities (health), and impairment of regular activities (symptom). Scores are calculated as impairment percentages. The WPAI-RA yields four types of scores: Absenteeism (work time missed), Presenteeism (impairment at work), Work productivity loss (overall work impairment), and Activity impairment.
| percentage of impairment | Placebo | Baricitinib | Adalimumab |
|---|---|---|---|
| Absenteeism Week 12 (n=160,168,118) | 0.5 ± 27.7 | -4.9 ± 20.6 | -0.5 ± 25.7 |
| Absenteeism Week 24 (n=118,139,102) | -1.6 ± 24.5 | -1.8 ± 25.2 | -3.2 ± 23.8 |
| Absenteeism Week 52 (n=0,124,92) | NA ± NA | -3.8 ± 25.1 | -3.7 ± 24.3 |
| Presenteeism Week 12 (n=147,160,113) | -11 ± 23 | -21 ± 26 | -16 ± 24 |
| Presenteeism Week 24 (n=110,134,99) | -11 ± 22 | -23 ± 27 | -22 ± 26 |
| Presenteeism Week 52 (n=0,119,88) | NA ± NA | -25 ± 27 | -25 ± 27 |
| Work Productivity Loss Week 12 (n=147,160,113) | -10.4 ± 24.3 | -21.6 ± 28.0 | -14.0 ± 25.6 |
| Work Productivity Loss Week 24 (n=110,134,99) | -9.0 ± 24.9 | -22.1 ± 30.2 | -21.4 ± 27.2 |
| Work Productivity Loss Week 52 (n=0,119,88) | NA ± NA | -24.4 ± 30.1 | -24.6 ± 29.8 |
| Activity Impairment Week 12 (n=458,474,315) | -11 ± 25 | -25 ± 26 | -20 ± 25 |
| Activity Impairment Week 24 (n=333,430,272) | -16 ± 26 | -28 ± 27 | -26 ± 26 |
| Activity Impairment Week 52 (n=0,396,240) | NA ± NA | -30 ± 27 | -28 ± 27 |
X-rays of the hands/wrists and feet were assessed for joint space narrowing (JSN) and bone erosions. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, is scored from 0 to 4, with 0 indicating no (normal) JSN and 4 indicating complete loss of joint space, bony ankylosis or luxation. JSN scores ranged from 0-168. A score of 0 would indicate no change and higher scores represent a worsening of joint space narrowing. The bone erosion score is a summary of erosion severity in 32 joints of the hands and 12 joints of the feet. Each joint is scored according to the surface area involved from 0 to 5 for hand joints and 0 to 10 for the foot joints, with 0 indicating no erosion and the highest score (5 for the hand and 10 for the foot) indicating extensive loss of bone from more than one half of the articulating bone. Erosion scores ranged from 0 (no erosion) to 280 (high erosion).
| units on a scale | Placebo | Baricitinib | Adalimumab |
|---|---|---|---|
| Joint Space Narrowing Week 24 (n= 452, 470, 312) | 0.27 ± 1.15 | 0.10 ± 0.74 | 0.09 ± 0.52 |
| Joint Space Narrowing Week 52 (n= 452, 473, 312) | 0.56 ± 2.33 | 0.18 ± 1.02 | 0.17 ± 1.00 |
| Bone Erosion Score Week 24 (n=452, 470, 312) | 0.57 ± 1.58 | 0.25 ± 1.12 | 0.20 ± 1.08 |
| Bone Erosion Score Week 52 (n= 452, 473, 312) | 1.15 ± 3.21 | 0.42 ± 1.91 | 0.34 ± 2.00 |
| nanomole/Liter (nmol/L) | Baricitinib |
|---|---|
| Population Pharmacokinetics (PK): Peak Concentration at Steady State (Cmax,ss) of Baricitinib | 143 ± 19.7 |
| nanomole*hr/Liter (nmol*hr/L) | Baricitinib |
|---|---|
| Population PK: Area Under the Concentration Versus Time Curve at a Dosing Interval at Steady State (AUCtau,ss) of Baricitinib | 1220 ± 45.8 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Treatment A | — | 26/488 (5.3%) | 177/488 (36.3%) |
| Baricitinib Treatment A | — | 26/487 (5.3%) | 196/487 (40.2%) |
| Adalimumab Treatment A | — | 7/330 (2.1%) | 132/330 (40%) |
| Placebo Treatment B | — | 12/306 (3.9%) | 58/306 (19%) |
| BaricitinibTreatment B | — | 16/424 (3.8%) | 70/424 (16.5%) |
| Adalimumab Treatment B | — | 9/267 (3.4%) | 38/267 (14.2%) |
| Rescue | — | 17/227 (7.5%) | 46/227 (20.3%) |
| Placebo Follow-up | — | 2/33 (6.1%) | 3/33 (9.1%) |
| Baricitinib Follow-up | — | 0/76 (0%) | 0/76 (0%) |
| Adalimumab Follow-up | — | 0/20 (0%) | 3/20 (15%) |
| Event | Placebo Treatment A | Baricitinib Treatment A | Adalimumab Treatment A | Placebo Treatment B | BaricitinibTreatment B | Adalimumab Treatment B | Rescue | Placebo Follow-up | Baricitinib Follow-up | Adalimumab Follow-up |
|---|---|---|---|---|---|---|---|---|---|---|
| PneumoniaInfections and infestations | 0/488 | 1/487 | 0/330 | 1/306 | 0/424 | 0/267 | 0/227 | 1/33 | 0/76 | 0/20 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 4/488 | 1/487 | 0/330 | 0/306 | 1/424 | 0/267 | 0/227 | 1/33 | 0/76 | 0/20 |
| SepsisInfections and infestations | 0/488 | 0/487 | 0/330 | 0/306 | 0/424 | 0/267 | 1/227 | 1/33 | 0/76 | 0/20 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/488 | 0/487 | 0/330 | 0/306 | 0/424 | 0/267 | 0/227 | 1/33 | 0/76 | 0/20 |
| AnaemiaBlood and lymphatic system disorders | 0/488 | 2/487 | 0/330 | 0/306 | 0/424 | 0/267 | 2/227 | 0/33 | 0/76 | 0/20 |
| EnterocolitisGastrointestinal disorders | 0/488 | 0/487 | 0/330 | 0/306 | 0/424 | 0/267 | 2/227 | 0/33 | 0/76 | 0/20 |
| FallInjury, poisoning and procedural complications | 0/488 | 0/487 | 0/330 | 2/306 | 0/424 | 0/267 | 0/227 | 0/33 | 0/76 | 0/20 |
| Urinary tract infectionInfections and infestations | 1/488 | 0/487 | 0/330 | 0/306 | 2/424 | 0/267 | 1/227 | 0/33 | 0/76 | 0/20 |
| Acute myocardial infarctionCardiac disorders | 0/488 | 0/487 | 0/330 | 0/306 | 1/424 | 0/267 | 1/227 | 0/33 | 0/76 | 0/20 |
| CholelithiasisHepatobiliary disorders | 1/488 | 0/487 | 0/330 | 0/306 | 0/424 | 0/267 | 1/227 | 0/33 | 0/76 | 0/20 |
| Event | Placebo Treatment A | Baricitinib Treatment A | Adalimumab Treatment A | Placebo Treatment B | BaricitinibTreatment B | Adalimumab Treatment B | Rescue | Placebo Follow-up | Baricitinib Follow-up | Adalimumab Follow-up |
|---|---|---|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 35/488 | 37/487 | 34/330 | 15/306 | 24/424 | 14/267 | 9/227 | 2/33 | 0/76 | 0/20 |
| Upper respiratory tract infectionInfections and infestations | 14/488 | 15/487 | 13/330 | 10/306 | 13/424 | 4/267 | 6/227 | 0/33 | 0/76 | 2/20 |
| Ovarian cystReproductive system and breast disorders | 0/488 | 0/487 | 0/330 | 0/306 | 0/424 | 0/267 | 0/227 | 0/33 | 0/76 | 1/16 |
| Urinary tract infectionInfections and infestations | 16/488 | 21/487 | 13/330 | 5/306 | 10/424 | 5/267 | 5/227 | 0/33 | 0/76 | 0/20 |
| HeadacheNervous system disorders | 12/488 | 14/487 | 13/330 | 0/306 | 0/424 | 0/267 | 0/227 | 0/33 | 0/76 | 0/20 |
| BronchitisInfections and infestations | 14/488 | 19/487 | 8/330 | 11/306 | 12/424 | 5/267 | 6/227 | 0/33 | 0/76 | 0/20 |
| PharyngitisInfections and infestations | 14/488 | 12/487 | 12/330 | 10/306 | 4/424 | 7/267 | 5/227 | 0/33 | 0/76 | 0/20 |
| AnaemiaBlood and lymphatic system disorders | 15/488 | 16/487 | 4/330 | 0/306 | 0/424 | 0/267 | 8/227 | 0/33 | 0/76 | 0/20 |
| HypertensionVascular disorders | 13/488 | 9/487 | 11/330 | 0/306 | 0/424 | 0/267 | 0/227 | 0/33 | 0/76 | 0/20 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 7/488 | 15/487 | 2/330 | 0/306 | 0/424 | 0/267 | 0/227 | 0/33 | 0/76 | 0/20 |
Modified Intent-to-Treat (mITT) population: all randomized participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Placebo | Baricitinib | Adalimumab | Total |
|---|---|---|---|---|
| Mean | 53.4 ± 11.8 | 53.5 ± 12.2 | 52.9 ± 12.3 | 53.3 ± 12.1 |
| Sex: Female, Male(Participants) | Placebo | Baricitinib | Adalimumab | Total |
|---|---|---|---|---|
| Female | 382 | 375 | 251 | 1008 |
| Male | 106 | 112 | 79 | 297 |
| Race (NIH/OMB)(Participants) | Placebo | Baricitinib | Adalimumab | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 26 | 19 | 18 | 63 |
| Asian | 148 | 143 | 101 | 392 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 4 | 2 | 4 | 10 |
| White | 302 | 312 | 204 | 818 |
| More than one race | 7 | 11 | 3 | 21 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
| Region of Enrollment(Participants) | Placebo | Baricitinib | Adalimumab | Total |
|---|---|---|---|---|
| Argentina | 91 | 107 | 57 | 255 |
| Belgium | 2 | 3 | 3 | 8 |
| Canada | 5 | 4 | 2 | 11 |
| China | 21 | 22 | 11 | 54 |
| Croatia | 1 | 0 | 0 | 1 |
| Czechia | 16 | 10 | 10 | 36 |
| France | 8 | 8 | 7 | 23 |
| Germany | 0 | 0 | 2 | 2 |
| Greece | 1 | 0 | 2 | 3 |
| Hungary | 18 | 11 | 8 | 37 |
| Japan | 93 | 93 | 63 | 249 |
| South Korea | 21 | 21 | 15 | 57 |
| Latvia | 2 | 2 | 5 | 9 |
| Lithuania | 4 | 12 | 10 | 26 |
| Mexico | 50 | 36 | 39 | 125 |
| Poland | 26 | 35 | 19 | 80 |
| Portugal | 1 | 1 | 1 | 3 |
| Romania | 8 | 6 | 2 | 16 |
| Russia | 27 | 28 | 23 | 78 |
| Slovakia | 8 | 8 | 4 | 20 |
| Slovenia | 4 | 1 | 0 | 5 |
| South Africa | 24 | 21 | 11 | 56 |
| Spain | 15 | 11 | 5 | 31 |
| Taiwan | 6 | 5 | 7 | 18 |
| United Kingdom | 2 | 6 | 0 | 8 |
| United States | 34 | 36 | 24 | 94 |
| Duration of Rheumatoid Arthritis(years) | Placebo | Baricitinib | Adalimumab | Total |
|---|---|---|---|---|
| Mean | 10.4 ± 8.7 | 10.3 ± 8.8 | 9.6 ± 8.5 | 10.1 ± 8.7 |
| Tender Joint Count of 68 Evaluable Joints(Number of Joints) | Placebo | Baricitinib | Adalimumab | Total |
|---|---|---|---|---|
| Mean | 23.3 ± 13.5 | 23.4 ± 13.0 | 23.4 ± 13.7 | 23.4 ± 13.3 |
| Swollen Joint Count of 66 Evaluable Joints(Number of Joints) | Placebo | Baricitinib | Adalimumab | Total |
|---|---|---|---|---|
| Mean | 15.5 ± 9.4 | 15.0 ± 8.2 | 15.4 ± 9.1 | 15.3 ± 8.9 |
| High Sensitivity C-Reactive Protein (hsCRP)(milligrams per liter (mg/L)) | Placebo | Baricitinib | Adalimumab | Total |
|---|---|---|---|---|
| Mean | 19.66 ± 20.97 | 22.20 ± 22.85 | 21.78 ± 20.83 | 21.14 ± 21.67 |
Showing the first 100 of 213 sites across 28 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
The record gives a start of Oct 2012, a primary completion of Mar 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2017, 2 years 5 months after primary completion. A results delay was requested in May 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Baricitinib